ArticleGynecology and minimally invasive therapy
A Decade-long Battle: Successful Stereotactic Radiotherapy for a Delayed Lung Metastasis from Endometrial Cancer.
Article in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary lung metastases more than 10 years after the resection of endometrial carcinoma are a rare occurrence. However, no cases have undergone stereotactic ablative radiotherapy (SABR) for solitary lung metastasis that developed more than 10 years after resection. A 76-year-old woman with a history of endometrial carcinoma 13 years prior was diagnosed with a lung tumor that was confirmed to be a metastasis from the endometrial carcinoma. Due to other health issues, the patient was not eligible for surgery and instead underwent SABR. The treatment was well-tolerated and no adverse events were reported during or up to 2 years after SABR. SABR may be considered as a safe and effective treatment option for lung metastases of endometrial carcinoma that develop more than 10 years after the initial treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.